VEGFA and neoplasm: In this context, ivonescimab (anti-PD-1 and VEGF), combined with chemotherapy, has demonstrated significant anti-tumor activity as a first-line therapy in advanced NSCLC without driver mutations or in patients resistant to prior treatments [190,191].